Long-term (up to 3.3 years) treatment with mavrilimumab, an antibody that targets granulocyte–macrophage colony-stimulating factor receptor-α, was safe and effective in patients with rheumatoid arthritis in two phase IIb studies and a phase II open-label extension study. In total, 442 patients received mavrilimumab in combination with methotrexate. In the extension study, 65.0% and 40.6% of patients achieved DAS28-CRP <3.2 and <2.6, respectively, at week 122. Most treatment-related adverse events were mild or moderate in severity.
References
Burmester, G. R. et al. Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis. Arthritis Rheumatol. https://doi.org/10.1002/art.40420 (2018)
Rights and permissions
About this article
Cite this article
Onuora, S. Long-term mavrilimumab safe and effective. Nat Rev Rheumatol 14, 122 (2018). https://doi.org/10.1038/nrrheum.2018.22
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2018.22